Today we welcome Brandy Wilkinson, CEO of GemPharmatech, and Rikki Feng, the company’s Neuroscience Pipeline Leader. 

Our discussion focuses on a persistent challenge in drug development: neurology’s stubbornly high clinical failure rates. GemPharmatech is tackling this head-on with proprietary models for Alzheimer’s, Parkinson’s, and blood-brain barrier transport that better mirror human disease biology.

We explore why mouse models matter more in neurology than in other fields, the design principles behind these next-generation tools, and how smarter preclinical partnerships can help therapeutic developers de-risk programs earlier. 

  • 00:00 Welcome Brandy Wilkinson and Rikki Feng
  • 03:17 GemPharmatech's mission
  • 06:26 Why mouse models matter in neurology
  • 11:11 Common translation gaps in neurology
  • 18:09 Designing proprietary neurological disease models
  • 25:45 Building stronger CRO strategic partnerships
  • 33:58 An optimistic future of neuroscience research

This episode was produced with the support of GemPharmatech. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Labiotech. Innehållet i podden är skapat av Labiotech och inte av, eller tillsammans med, Poddtoppen.